Lilly Wins Ruling Blocking Generic Forms of Top-Selling Zyprexa
April 14 (Bloomberg) -- Eli Lilly & Co. won a court ruling that will prevent generic-drug makers from selling low-cost versions of its $4.4 billion-a-year Zyprexa schizophrenia drug before 2011.
U.S. District Judge Richard L. Young's decision to uphold the patent on the key ingredient in Zyprexa is a defeat for Ivax Corp., Dr. Reddy's Laboratories Ltd. and Teva Pharmaceutical Industries Ltd., which wanted to sell copies of the drug. The ruling was posted on the Indianapolis court's Web site today.
